(CNBC) The U.S. Food and Drug Administration on Monday authorized emergency use of Eli Lilly’s experimental Covid-19 antibody treatment for non-hospitalized patients older than 65 or who have certain chronic medical conditions. The FDA said its emergency use authorization (EUA) was based on clinical trials showing that the treatment, bamlanivimab, reduced the need for hospitalization or emergency room visits in Covid-19 patients at high risk of disease progression.
U.S. allows emergency use of Eli Lilly’s Covid antibody therapy
This entry was posted in Syndicated. Bookmark the permalink.